skip to main content
Idioma:

Noacs replace VKA as preferred oral anticoagulant among new patients

Van Den Heuvel, Jan Maurik ; Hövels, Anke M ; Büller, Harry R ; Mantel-Teeuwisse, A.K ; De Boer, A ; Maitland-Van Der Zee, A.H

2017

Texto completo disponível

Citações Citado por
  • Título:
    Noacs replace VKA as preferred oral anticoagulant among new patients
  • Autor: Van Den Heuvel, Jan Maurik ; Hövels, Anke M ; Büller, Harry R ; Mantel-Teeuwisse, A.K ; De Boer, A ; Maitland-Van Der Zee, A.H
  • Assuntos: adult ; aged ; antivitamin K ; bleeding ; calculation ; clinical trial ; drug combination ; drug therapy ; female ; gender ; human ; international normalized ratio ; major clinical study ; male ; monitoring ; Netherlands ; pharmacy ; physician ; prescription ; Taverne ; thromboembolism
  • Notas: 1053-8569
    Pharmacoepidemiology and Drug Safety 26, 565-566 (2017)
    https://dspace.library.uu.nl/handle/1874/428182
  • Descrição: Background: In 2012, around 400,000 patients in the Netherlands were treated with vitamin K antagonists (VKA) for thromboembolic diseases. Since 2011, non-VKA oral anticoagulants (NOACs) have been available. NOACs do not require frequent INR monitoring and cause less bleeding, which benefits patients, but also imposes a risk of reduced therapy adherence. Objectives: The objective of this study is to describe uptake of and patient compliance with NOACs in The Netherlands between July 2011 and October 2016. Methods: We analysed prescription data for 247.927 NOAC and/or VKA patients across 560 pharmacies. All patients who received at least one prescription of either VKA or NOACs between 1 July 2011 and 30 September 2016 were included in the study. Our database contained (not exhaustive) the following information about the prescriptions: dispensed medication and quantity, dispensing date, prescribed dosage and prescriber type, patient age and gender. We used these data to describe patient profiles, uptake of NOACs among new naïve patients and switch of patients between VKA and NOACs. We developed an algorithm to classify patients as new naïve starters, switcher or repeat patients. We calculated therapy compliance as the percentage of days covered (PDC). To obtain reliable results, in our PDC calculations we included only patients with a time period of at least 12 months between their first and last prescription. Results: During the studied period the share of NOACs in oral anticoagulants has grown to 57% of prescriptions to new patients. More than 70% of new NOAC users were new naïve patients and around 26% switched from VKA. The overall share of NOACs among starters is largest in the group of patients of 50-80 years. Calculated percentages of days covered (PDC) for NOAC patients show that 87% of all users were compliant. Conclusions: NOACs have overtaken VKA as the major treatment prescribed to patients starting on oral anticoagulants, and the number of starters on VKA is at present decreasing. We expect that almost all oral anticoagulants prescribed to new patients will be NOACs. NOAC users are in general compliant with therapy. This may provide additional confidence to physicians in prescribing NOACs instead of VKAs.
  • Data de criação/publicação: 2017
  • Idioma: Inglês
Voltar para lista de resultados
Ir para página anteriorAnterior Resultado  9 AvançarIr para próxima página

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.